Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population.

Because of the strong association with the use of rituximab with longer survival (we found evidence for a 30% reduction in risk in those treated, although not strictly significant at 0.05 level), even after adjusting for calendar year, the difference in risk associated with HIV status was strongly attenuated after controlling for use of rituximab alone.

also in 41 other papers